Mr. Purcell is the original Founder of Aisling Capital LLC. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.
Mr. Purcell has served as a director of Aton Pharma (acquired by Merck), Bridge Pharmaceuticals (acquired by Pharmaron), Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. Mr. Purcell also served as a member of the Section Governing Board at BIO (“Biotechology Innovation Organization”), the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the Boards of Real Endpoints, Summus Global, Inc., BioScience Managers, and Ichnos Sciences. He sits on the Editorial Advisory Board at Life Science Leader Magazine; Member of the Board at NYBIO Association; Board Member at The University of Delaware Investment Visiting Committee as well as a member of the Biopharmaceutical Innovation Board at the University of Delaware.
Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.
Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.
Mr. Purcell has served as a director of Aton Pharma (acquired by Merck), Bridge Pharmaceuticals (acquired by Pharmaron), Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. Mr. Purcell also served as a member of the Section Governing Board at BIO (“Biotechology Innovation Organization”), the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the Boards of Real Endpoints, Summus Global, Inc., BioScience Managers, and Ichnos Sciences. He sits on the Editorial Advisory Board at Life Science Leader Magazine; Member of the Board at NYBIO Association; Board Member at The University of Delaware Investment Visiting Committee as well as a member of the Biopharmaceutical Innovation Board at the University of Delaware.
Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.
Speaking In
1:00 PM - 2:00 PM
Monday, June 5
